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Abstract
With on-line hemodiafiltration (HDF), low molecular weight substances are predominantly cleared
by diffusion while middle molecules such as ß2-microglobulin (ß2M), an amyloidogenic factor, are
removed mainly by convection. The objectives of this study are to evaluate the cost-effectiveness
and safety of on-line HDF with dialyzer reuse, and to compare HDF and high-flux hemodialysis
(HD) with respect to ß2M removal, urea kinetics (Kt/V) and symptom relief in those patients having
dialysis-related amyloidosis. Ten chronic HD patients were put on post-dilution HDF for a period of
14.2 ±7.1 months. The AK 100 ULTRA system was used for on-line preparation of substitution
fluid. These patients were then switched over to high-flux HD for a period of 4.6 ±3 months. Dialyzers
were reused up to 30 times to reduce the cost of HDF. All the patients were hemodynamically
stable during both HDF and high-flux HD treatments. No febrile reactions were reported. The
percentage reduction of ß2M during HDF was significantly higher when compared with high-flux
HD (75 ±4% vs 51 ±7%, p < 0.001). After 14.2 ±7.1 months of HDF, the patients had significant
reduction of both the pre-dialysis ß2M level (47.4 ±7.9 µg/mL vs 28.2 ±4.9 µg/mL, p < 0.01) and
post-dialysis ß2M level (11.4 ±2.8 µg/mL vs 6.8 ±1.0 µg/mL, p < 0.01). eKt/V achieved by HDF was
significantly higher than that achieved by high-flux HD (1.94 ±0.26 vs 1.75 ±0.23, p < 0.01). Those
patients with dialysis arthropathy and carpal tunnel syndrome had decreased joint pain and hand
numbness respectively after putting on HDF but symptoms recurred while on high-flux HD. There
were no statistical significant differences in the percentage reduction of ß2M, ß2M clearance, urea
clearance and eKt/V with dialyzer reuse, and no adverse patient reactions had been recorded.
Conclusions: On-line HDF has been proven to be a safe and reliable treatment. The clearance of
ß2M and urea are significantly increased by HDF when compared with high-flux HD, and the
increase in clearance of ß2M is sustained throughout the HDF treatment period. Symptoms of
dialysis-related amyloidosis are improved by HDF. Dialyzer reuse, which reduces the cost of HDF
by 30%, is feasible and safe.
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INTRODUCTION
Hemodiafiltration (HDF) as a blood purification method
is  a  combinat ion of  hemodialysis  (HD) and
hemofiltration. HD is a transport process by which a
solute passively diffuses  down its concentration gradient
from one fluid compartment to another. Hemofiltration
refers to use of a hydrostatic pressure gradient to induce
the convection of plasma water across the membrane of
the hemofilter. The frictional force between water and
solutes, which is called solvent drag, results in the
convective transport of solutes in the same direction as
water. HDF therefore removes toxins by convection in
addition to diffusion. The rate of solute transport by
diffusion decreases more rapidly with increasing size of
molecules than that by convection (1). Theoretically,
middle molecules such as ß2-microglobulin (ß2M) are
therefore better removed by convection.
The AK 100 ULTRA (Gambro, Lund, Sweden) is a
system for HD, hemofiltration and HDF using on-line
prepared bicarbonate dialysate and substitution solution.
After being prepared from reverse osmosis water, the
fluid is pre-filtered through a U8000 ultrafilter (2.2 m2
polyamide, Gambro, Lund, Sweden) before entering the
machine. A (acidic)- and B (bicarbonate)-concentrates
are then added to the fluid. To ensure a high level of
microbiological quality, the bicarbonate solution is
prepared from a dry powder, BiCart® (Gambro, Lund,
Sweden). This prepared fluid is filtered through a second
U8000 ultrafilter and is used as sterile dialysate in HD
and HDF treatments. The substitution fluid required for
hemofiltration and HDF treatments is filtered through a
third, final U2000 ultrafilter (0.2 m2 polyamide, Gambro,
Lund, Sweden) before being infused into the patient's
blood line. To ensure a high microbiological quality of
the fluid, the machine is filled with peracetic acid when
not in use during nights and weekends. The two U8000
ultrafilters are included in the disinfection loop and
replaced every 2 weeks. The final U2000 filter is
disposable together with the infusion line.
The primary aim of the study was to evaluate the cost-
effectiveness and safety of the AK 100 ULTRA system
for on-line preparation of substitution fluid and HDF
treatment with dialyzer reuse. The secondary aim was to
compare HDF and high-flux HD with respect to ß2M
removal, urea kinetics (Kt/V) and symptom relief in those
patients having dialysis-related amyloidosis.
PATIENTS AND METHODS
A prospective cross-over study was performed on 10
chronic HD patients (5 females and 5 males) with a mean
duration of HD of 10.1 ±6.1 years. Six of them had been
put on continuous ambulatory peritoneal dialysis for a
mean duration of 11.6 ±17.3 months before conversion
to chronic HD. Their mean age was 40.2 ±7.8. Four of
the patients had proven dialysis-related amyloidosis by
magnetic resonance imaging. Three of them had
involvement of the shoulder joints and one had
involvement of both the shoulder and wrist joints. All of
them were symptomatic with arthralgia over the involved
joints. Three of these four patients also had documented
carpal tunnel syndrome secondary to dialysis-related
amyloidosis. All of them had release operations
performed but symptom of hand numbness recurred after
operation. These four patients with dialysis-related
amyloidosis had been receiving chronic HD for a mean
duration of 15 ±2.6 years.
The 10 patients were put on post-dilution HDF using the
AK 100 ULTRA on-line system for a period of 14.2 ±7.1
months. The mean blood flow rate was 249 ±13 mL/
minute and the mean infusion volume of substitution fluid
was 18.9 ±1.3 L per HDF treatment. They were then
switched over to high-flux HD for a period of 4.6 ±3
months with a mean blood flow rate of 241 ±24 mL/
minute. The same dialysis machine was used during the
high-flux HD period. There was no significant difference
in the mean blood flow rate between the two modes of
dialysis treatment (p = 0.134). All the patients were
receiving dialysis twice weekly with duration of 5 hours
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per session for both modes of treatment. All the
treatments were performed with high-flux dialyzer
(F60S, Fresenius Medical Care, Bad Homburg,
Germany), made of synthetic membrane, polysulfone,
with a surface area of 1.3 m2. The prescribed substitution
fluid composition (in mmol/L) was: sodium 135 to140,
potassium 2, calcium 1.75, magnesium 0.5, chloride
109.5, bicarbonate 30 to 35, acetate 3. The temperature
of the substitution fluid was kept at 37 oC during all the
dialysis treatments. The dialysate flow rate was set at
500 mL/minute. The treatment time, number of
treatments per week, type of dialyzer and dialysate flow
rate were kept unchanged during the whole study period.
Blood pressure, heart rate, body temperature and body
weight were recorded before and after treatment. Pre-
dialysis blood samples were collected monthly for
analysis of blood chemistries. Blood samples for assay
of ß2M and urea levels were obtained pre-dialysis and
30 minutes post-dialysis at monthly interval. The
percentage reduction of ß2M was calculated from the pre-
and post-dialysis levels. The pre-dialysis and post-
dialysis ß2M levels before and after the HDF period, and
after the high-flux HD period were recorded. Equilibrated
Kt/V (eKt/V) was computed from the pre and post-
dialysis urea levels using the Daugirdas second
generation equation (2):
eKt/V = - ln ( Ct/Co - 0.008 t ) + ( 4 - 3.5 Ct/Co ) x UF/W
Co = pre-dialysis urea level, mmol/L
Ct = equilibrated post-dialysis urea level, mmol/L
t = time of dialysis, hour
UF = ultrafiltration volume, L
W = post-dialysis body weight, kg
The equilibrated post-dialysis urea level was sampled at
30 minutes after the end of dialysis. Symptoms of dialysis
arthropathy (joint pain) and carpal tunnel syndrome (hand
numbness) were evaluated before the commencement of
HDF, at the end of HDF treatment period and at the end
of high-flux HD period by using questionnaires.
During the period of high-flux HD, the polysulfone
dialyzers were reused up to 30 times to reduce the cost
of the dialysis treatment. The percentage reduction of
ß2M, ß2M clearance, urea clearance and eKt/V during
the first use of dialyzer were compared with that during
the thirtieth use of dialyzer. The ß2M clearance and urea
clearance were computed as the blood flow rate times
the percentage reduction across the dialyzer in the plasma
solute (ß2M or urea) concentration (3). The percentage
reduction of ß2M or urea level across the dialyzer was
obtained by sampling the dialyzer inlet and dialyzer outlet
blood levels. The blood flow rate was maintained the
same during the first use and the thirtieth use of dialyzer.
The disinfectant used for dialyzer reprocessing was
Renalin® PA Cold Sterilant (Minntech Renal Systems,
Minneapolis, U.S.A.) which contains 20% of hydrogen
peroxide, 4% of peracetic acid and 76% of inert
ingredients. The Renatron® Automated Dialyzer
Reprocessing System (Minntech Renal Systems,
Minneapolis, U.S.A.) was used for reprocessing of
dialyzer.
Fluid samples for microbiological evaluation were
collected every 2 weeks from two different positions of
the AK 100 ULTRA system: position 1: after the first
U8000 ultrafilter; position 2: after the second U8000
ultrafilter at the infusion port. Fluid samples were
cultivated on Tryptone Glucose Extract Agar for 7 days
at 22 oC.
The paired Student's t-test was used to compare the mean
percentage reduction of ß2M and eKt/V between HDF
and high-flux HD, and the mean body temperature before
and after HDF/high-flux HD treatment. The non-
parametric Wilcoxon Signed Ranks test was used to
compare the mean pre-dialysis and post-dialysis ß2M
level before and after the HDF treatment period, and after
the high-flux HD period. The test was also used to
compare the mean percentage reduction of ß2M, ß2M
clearance, urea clearance and eKt/V between the first
use and thirtieth use of the dialyzer.
RESULTS
The hemodynamic parameters: blood pressure, heart rate
and body temperature were all stable during both the
HDF period (Table 1) and the high-flux HD period
(Table 2). There were no hypotensive episodes or febrile
reactions during both periods. There was no significant
difference in body temperature before and after the
dialysis session during both the HDF period (p = 0.684)
and the high-flux HD period (p = 0.362) (Table 1,2).
Changes in body weight were in the expected ranges for
a session of dialysis treatment. All the patients tolerated
Table 1.  Patient parameters, HDF period (Mean ±SD, n = 30).
SBP (mmHg) DBP (mmHg) Heart Rate (beats/min) Body temperature (oC) BW (kg)
Pre-treatment 158 ±12 87 ±12 78 ±15 36.4 ±0.3 49.3 ±6.3
Post-treatment 149 ±21 84 ±12 77 ±14 36.5 ±0.3 46.6 ±6.3
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both types of treatment well. All the blood chemistries
remained stable during the study period.
The percentage reduction of ß2M during HDF and high-
flux HD are shown in table 3. The percentage reduction
of ß2M during HDF was significantly higher when
compared with high-flux HD (75 ±4% vs 51 ±7%, p <
0.001). After 14.2 ±7.1 months of HDF, the pre-dialysis
ß2M level was significantly reduced (47.4 ±7.9 µg/mL
vs 28.2 ±4.9 µg/mL, p < 0.01) (Table 4). The post-dialysis
level was also significantly decreased (11.4 ±2.8 µg/mL
vs 6.8 ±1 µg/mL, p < 0.01) (Table 4). However, after
switching over to high-flux HD for a period of 4.6 ±3
months, the pre-dialysis ß2M level increased back to
33.3 ±4 µg/mL (p < 0.05) and the post-dialysis level
increased back to 11.3 ±2.5 µg/mL (p < 0.01) (Table 5).
With regard to urea kinetics, the eKt/V achieved by HDF
was significantly higher than that achieved by high-flux
HD (1.94 ±0.26 vs 1.75 ±0.23, p < 0.01) (Table 3).
All the four patients with dialysis arthropathy had
decreased joint pain after being on HDF for 20 ±5.8
months but symptoms recurred when switching to high-
flux HD. Three of these patients also had a recurrence of
carpal tunnel syndrome after release operation. All of
them had improvement in hand numbness while on HDF
but symptoms relapsed after conversion to high-flux HD.
With dialyzer reuse, there were no significant differences
in percentage reduction of ß2M, ß2M clearance, urea
clearance and eKt/V during the first use and the thirtieth
use of dialyzer (Table 6). No adverse patient reactions
had been reported during dialyzer reuse. By reusing the
polysulfone dialyzer 30 times, the cost of HDF can be
reduced by 30%. Table 7 shows the reduction of the costs
of HDF and high-flux HD with reuse of polysulfone
dialyzer three, six and 30 times.
Microbiological analysis of the substitution fluid from
two different positions of the system revealed that only
five out of 55 fluid samples from position 1 had positive
culture. Positive culture was expressed as number of
colony forming unit (CFU) per 1000 mL substitution
fluid. Amount the five positive cultures, the maximum
value was only 3 CFU/1000 mL. No positive culture was
found in 57 fluid samples from position 2. The high
quality of the substitution fluid was also reflected by the
absence of febrile reactions or adverse events during HDF
treatment in all the patients.
DISCUSSIONS
In Hong Kong, similar to most Asian countries, the organ
donation rate is low. More than 1000 end-stage renal
failure patients were on the waiting list for renal
transplant. Many of these patients stayed on dialysis for
many years. From the data of the Hong Kong Renal
Registry, as of 31 March 1999, there were 3066 patients
on dialysis. Among these 3066 dialysis patients, 13%
were receiving chronic HD (4). These patients were prone
to develop long-term complications of chronic HD.
Dialysis-related amyloidosis is one of these long-term
Table 2.  Patient parameters, high-flux HD period (Mean ±SD, n = 30).
SBP (mmHg) DBP (mmHg) Heart Rate beats/min Body temperature (oC) BW (kg)
Pre-treatment 139 ±21 76 ±13 75 ±13 36.5 ±0.3 49.4 ±6.4
Post-treatment 143 ±20 81 ±13 77 ±14 36.5 ±0.4 46.8 ±6.5
Table 3.  ß2M % reduction and urea kinetics (eKt/V) (Mean ±SD,
n = 30).
HDF High-flux HD p value
ß2M % reduction 75 ±4 51 ±7 < 0.001
eKt/V 1.94 ±0.26 1.75 ±0.23 < 0.01
Table 4.  Pre-dialysis and post-dialysis ß2M levels after 14.2 ±7.1 months of HDF (Mean ±SD, n = 10).
At the start of HDF period At the end of HDF period p value
Pre-dialysis ß2M level, µg/mL 47.4 ±7.9 28.2 ±4.9 < 0.01
Post-dialysis ß2M level, µg/mL 11.4 ±2.8 6.8 ±1.0 < 0.01
Table 5.  Pre-dialysis and post-dialysis ß2M levels after 4.6 ±3.0 months of high-flux HD (Mean ±SD, n = 10).
At the end of HDF period At the end of high-flux HD period p value
Pre-dialysis ß2M level, µg/mL 28.2 ±4.9 33.3 ±4.0 < 0.05
Post-dialysis ß2M level, µg/mL 6.8 ±1.0 11.3 ±2.5 < 0.01
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complications. A prospective postmortem study has
detected joint amyloid deposition in 21% of patients
requiring HD for less than 2 years, 50% at 4 to 7 years,
90% at 7 to 13 years, and 100% at more than 13 years
(5). For clinical symptomatic disease, the prevalence was
0% at 5 years but increased to approximately 50% at 12
years, and was almost 100% at 20 years (6). ß2M has
been shown to be the major component of amyloid
deposits in dialysis-related amyloidosis (7) and plays an
important role in the pathogenesis of dialysis-related
amyloidosis (8-11).
HDF, which removes toxins by convection in addition
to diffusion, has been shown to remove ß2M more
efficiently then HD (12-14). In this regard, our study
has demonstrated a better removal of ß2M by HDF when
compared with high-flux HD. In addition, we also
demonstrated a sustained reduction of ß2M throughout
the HDF treatment period as evidenced by the decline in
both the pre-dialysis and post-dialysis levels after the
HDF treatment period. This reduction of ß2M during the
HDF period was attenuated after switching over to high-
flux HD. HDF also resulted in better clearance of small
molecules such as urea when compared with high-flux
HD as shown by a significantly higher eKt/V achieved
by HDF than that achieved by high-flux HD. Kim et al
had demonstrated a significant improvement in shoulder
pain secondary to dialysis-related amyloidosis when ß2M
were efficiently removed during post-dilution HDF (13).
For those patients with symptomatic dialysis-related
amyloidosis, our study has shown that HDF was superior
to high-flux HD in alleviating the joint pain of dialysis
arthropathy and hand numbness of carpal tunnel
syndrome. On-line HDF was well tolerated by all the
patients in the study as reflected by their stable
hemodynamic parameters and the absence of febrile
reactions during treatment.
Today only a limited number of patients in Hong Kong
are treated with HDF, mainly because of the cost of the
substitution solution and dialysis consumables. The on-
line production of substitution solution is a major
breakthrough in the reduction of cost. However, the
expensive high-flux dialyzers and bacterial ultrafilters
are the other factors that hinder the development of a
large-scale HDF program. In Hong Kong, only less than
2% of the HD patients were put on HDF. Reuse of
dialyzers can reduce the cost of dialysis while achieving
an acceptable quality of both small molecule and middle
molecule clearance. We have found no significant
differences in the percentage reduction of ß2M, ß2M
clearance, urea clearance and eKt/V with dialyzer reuse.
The reduction of consumable cost of on-line HDF is
around 30% by reusing dialyzer up to 30 times.
CONCLUSIONS
HDF with on-line preparation of bicarbonate dialysate
and substitution solution by the AK 100 ULTRA system
has been proven to be a safe and reliable treatment in
patients with end-stage renal disease. Reuse of dialyzer
increases the cost-effectiveness of on-line HDF. No
adverse patient reactions have been recorded during HDF
treatment and dialyzer reuse. The substitution fluid has
been shown to be of excellent microbiological quality.
HDF has a definite advantage over high-flux HD in terms
of ß2M removal and urea kinetics (Kt/V). It is more
efficient than high-flux HD in alleviating the symptoms
of dialysis arthropathy and carpal tunnel syndrome in
chronic HD patients with established dialysis-related
amyloidosis.
Table 6.  Reuse of dialyzer (Mean ±SD, n = 10).
First use of dialyzer 30th use of dialyzer p value
ß2M % reduction 54 ±6 53 ±5 0.445
ß2M clearance (mL/min) 49 ±15 47 ±9 0.959
Urea clearanc (mL/min) 211 ±18 208 ±18 0.721
eKt/V 1.80 ±0.17 1.72 ±0.28 0.445
Table 7.  Reduction of cost of HDF by reusing dialyzer.
                                          Cost of one session dialysis treatment (HK$)
Number of dialyzer reuse HDF High-flux HD Conventional HD
Single use 780 724 388
3 times 626 570
6 times 581 525
30 times 545 489
(30% cost reduction)
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